Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPH-104 (Goflikicept) in Idiopathic Recurrent Pericarditis
NCT04692766Phase 3Completed
- Sponsor
- R-Pharm
- Start
- Feb 2020
- Primary completion
- Jan 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic recurrent pericarditis (IRP) comparing RPH-104 with Placebo (2 arms). Primary endpoint: Time to recurrence of pericarditis at 24 weeks. Started Feb 2020; status: completed.
02
Drugs
goflikicept
03
Conditions
idiopathic recurrent pericarditis (IRP)
Beyond the preview
Go deeper on NCT04692766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04692766.